Zoetis announces results of Its annual meeting of shareholders and declares third quarter 2020 dividend.
Top Research Reports for Amgen, BHP, Altria & Others
Fund reveals 1st-quarter trades Continue reading...
Zoetis reports first quarter 2020 financial results.
Zoetis (ZTS) beats on earnings in the first quarter of 2020 while sales meet estimates. Domestic revenues bumped up owing to growth in new parasiticide products and a robust dermatology portfolio.
Moody's Investors Service ("Moody's") assigned a Baa1 rating to the proposed senior unsecured bond offering of Zoetis Inc. ("Zoetis"). There are no changes to Zoetis' existing ratings including the Baa1 senior unsecured rating and the Prime-2 commercial paper rating. Zoetis' Baa1 rating reflects its strong position as the world's largest producer of pharmaceuticals for animal health, and its good business diversity across geographic regions, therapeutic categories, species, and products.
ZTS earnings call for the period ending March 31, 2020.
Zoetis, the largest animal-health company, reported solid first-quarter results but warned there will be more fallout from Covid-19 and the accompanying recession.
PCRX vs. ZTS: Which Stock Is the Better Value Option?
The animal health company now projects lower revenue and earnings this year as a result of the pandemic.
Zoetis announces pricing of $1.25 billion of senior notes
Q1 2020 Zoetis Inc Earnings Call
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
All of this, to me, is a perfect recipe for continued pet industry growth no matter the economic condition. Chewy is an e-commerce pet supplier. They benefit from the double-whammy of a strong pet industry and the tailwind of e-commerce.
Zoetis (ZTS) delivered earnings and revenue surprises of 7.95% and 1.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) will provide pipeline updates along with financial numbers for the first quarter in its impending earnings release.
Pharmaceutical stocks dipped by a double-digit percentage in the first four months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
Zoetis to present at the Stifel 2020 Virtual Jaws and Paws Conference on May 27th.
Animal-health giant Zoetis beat Wall Street's first-quarter expectations Wednesday, but Zoetis stock toppled on its trimmed full-year outlook. The company doesn't expect an impact on R&D.